BG104076A - Комбинирано лечение включващо амплодипин и статиново съединение - Google Patents

Комбинирано лечение включващо амплодипин и статиново съединение

Info

Publication number
BG104076A
BG104076A BG104076A BG10407600A BG104076A BG 104076 A BG104076 A BG 104076A BG 104076 A BG104076 A BG 104076A BG 10407600 A BG10407600 A BG 10407600A BG 104076 A BG104076 A BG 104076A
Authority
BG
Bulgaria
Prior art keywords
combinations
pharmaceutically acceptable
patients
amplodipin
statine
Prior art date
Application number
BG104076A
Other languages
English (en)
Inventor
Jan Buch
Robert Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104076A publication Critical patent/BG104076A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Изобретението се отнася до фармацевтични комбинации на амлодипин или негова фармацевтично приемлива, присъединителна с киселина сол, и статини и техни фармацевтично приемливи соли, съдържащи такива комбинации, до китове, включващи такива комбинации,и до методи за тяхното използване при лечение на пациенти, страдащи от ангина пекторис, атеросклероза, комбинация от високо кръвно налягане с хиперлипидемия и на пациенти с риск от сърдечни заболявания. Изобретението се отнася също и до сумарни и синергитични комбинации на амлодипин или негова фармацевтично приемлива, присъединителна с киселина сол и статини и техни фармацевтично приемливи соли, които комбинации са приложими при лечение на пациенти, страдащи от ангина пекторис, атеросклероза, комбинация на хипертония с хиперлипидемия, както и на пациенти със симптоми за риск от сърдечни заболявания.
BG104076A 1997-08-29 2000-01-13 Комбинирано лечение включващо амплодипин и статиново съединение BG104076A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29
PCT/IB1998/001220 WO1999011263A1 (en) 1997-08-29 1998-08-10 Combination therapy comprising amlodipine and a statin compound

Publications (1)

Publication Number Publication Date
BG104076A true BG104076A (bg) 2000-09-29

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104076A BG104076A (bg) 1997-08-29 2000-01-13 Комбинирано лечение включващо амплодипин и статиново съединение

Country Status (37)

Country Link
US (1) US20020025981A1 (bg)
EP (1) EP1003507A1 (bg)
JP (1) JP2001514224A (bg)
KR (1) KR20010022385A (bg)
CN (1) CN1117566C (bg)
AP (1) AP1207A (bg)
AR (1) AR017514A1 (bg)
AU (1) AU744982B2 (bg)
BG (1) BG104076A (bg)
BR (1) BR9811558A (bg)
CA (1) CA2296726C (bg)
CO (1) CO4970726A1 (bg)
DZ (1) DZ2600A1 (bg)
EA (1) EA002705B1 (bg)
GT (1) GT199800134A (bg)
HK (1) HK1029530A1 (bg)
HN (1) HN1998000124A (bg)
HR (1) HRP980475A2 (bg)
HU (1) HUP0003103A3 (bg)
ID (1) ID24275A (bg)
IL (2) IL133957A0 (bg)
IS (1) IS5345A (bg)
MA (1) MA26539A1 (bg)
NO (1) NO20000999L (bg)
NZ (1) NZ502283A (bg)
OA (1) OA11289A (bg)
PA (1) PA8457201A1 (bg)
PE (1) PE106999A1 (bg)
PL (1) PL339088A1 (bg)
SA (1) SA98190432A (bg)
SK (1) SK1392000A3 (bg)
TN (1) TNSN98158A1 (bg)
TR (1) TR200000562T2 (bg)
UY (1) UY25159A1 (bg)
WO (1) WO1999011263A1 (bg)
YU (1) YU2700A (bg)
ZA (1) ZA987843B (bg)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
EP2000137B1 (en) 2006-03-29 2015-10-21 Kowa Company, Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR101181172B1 (ko) * 2008-02-22 2012-09-18 한올바이오파마주식회사 방출성이 제어된 시간차 투여 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
TW201628625A (zh) * 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
EP3706799A4 (en) * 2017-11-10 2021-08-25 Op-T Llc PROCEDURES FOR THE PREVENTION, MODULATION AND / OR REDUCTION OF CARDIOVASCULAR DISEASES
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
WO2021108343A1 (en) * 2019-11-25 2021-06-03 Fordoz Pharma C0Rp. Formulations comprising lipid-lowering and blood pressure-lowering drugs
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (bg) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
EP1003507A1 (en) 2000-05-31
CO4970726A1 (es) 2000-11-07
US20020025981A1 (en) 2002-02-28
PL339088A1 (en) 2000-12-04
IL133957A0 (en) 2001-04-30
TR200000562T2 (tr) 2000-08-21
WO1999011263A1 (en) 1999-03-11
HUP0003103A3 (en) 2002-03-28
BR9811558A (pt) 2000-08-22
NO20000999D0 (no) 2000-02-28
CN1117566C (zh) 2003-08-13
IS5345A (is) 2000-01-14
KR20010022385A (ko) 2001-03-15
HK1029530A1 (en) 2001-04-06
HRP980475A2 (en) 1999-06-30
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
MA26539A1 (fr) 2004-12-20
PA8457201A1 (es) 2000-05-24
JP2001514224A (ja) 2001-09-11
IL133957A (en) 2006-06-11
ID24275A (id) 2000-07-13
NZ502283A (en) 2002-05-31
ZA987843B (en) 2000-02-28
CA2296726C (en) 2004-06-29
HUP0003103A2 (hu) 2001-01-29
YU2700A (sh) 2002-06-19
CA2296726A1 (en) 1999-03-11
EA002705B1 (ru) 2002-08-29
AU744982B2 (en) 2002-03-07
CN1268054A (zh) 2000-09-27
AR017514A1 (es) 2001-09-12
DZ2600A1 (fr) 2003-03-01
EA200000013A1 (ru) 2000-08-28
AP9801333A0 (en) 1998-09-30
AU8458598A (en) 1999-03-22
NO20000999L (no) 2000-02-28
UY25159A1 (es) 2000-12-29
GT199800134A (es) 2000-02-08
AP1207A (en) 2003-09-20
SA98190432A (ar) 2005-12-03
HN1998000124A (es) 1999-02-09

Similar Documents

Publication Publication Date Title
BG104076A (bg) Комбинирано лечение включващо амплодипин и статиново съединение
BG104177A (bg) Фармацевтичен състав и използването му като лекарствено средство
RU93036185A (ru) Ингибиторы с двойным действием
CA2210889A1 (en) Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
CA2179521A1 (en) 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps
BG100635A (bg) Заместени n-(индол-2-карбонил)-бета-аланинамиди и техни производни като антидиабетични средства
CA2218555A1 (en) Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
EP2289521A3 (en) Compositions and methods for use in tergeting vascular destruction
CA2375225A1 (en) Mutual salt of amlodipine and atorvastatin
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
CY1107763T1 (el) Εναντιομερεις ενωσεις για την αγωγη καρδιακων αρρυθμιων και μεθοδοι χρησεως
EA200301223A1 (ru) Лекарственные формы окскарбазепина
BR9915610A (pt) Preparações farmacêuticas combinadas
CA2296637A1 (en) Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containingit
RU93055870A (ru) Производные бифенила, способ их получения и фармацевтическая композиция для лечения гипертонии и сердечных заболеваний
CO5170457A1 (es) Profarmacos mutuos de amlodipino y atorvastatina
MX9707683A (es) Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler
MX9603300A (es) Derivados de la 4-sulfonilbenzoilguanidina o la 4-sulfinilbenzoilguanidina.
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
UA41353C2 (uk) Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність
HUP9800810A2 (hu) Kombinációs terápia emberi immunhiány-vírusos (HIV) ferőzés kezelésére